Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab.

Claudia Campani,Jessica Bamba-Funck,Bertille Campion,Sabrina Sidali,Lorraine Blaise,Nathalie Ganne-Carrié,Alix Demory,Olivier Sutter,Edouard Larrey,Manon Evain,Haroun Ghannouchi,Mathilde Wagner,Fabio Marra,Angela Sutton,Manon Allaire,Jean-Charles Nault

Liver international : official journal of the International Association for the Study of the Liver（2023）

引用 9|浏览15

暂无评分

摘要

AFP early response at 3 weeks predicts oncological outcomes in HCC patients treated with AtezoBev and combination with ALBI grade refines prognostic discrimination.

查看译文

关键词

advanced hepatocellular carcinoma,alpha-foetoprotein,atezolizumab-bevacizumab,biomarker,early response,immunotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要